[{"orgOrder":0,"company":"Max Zeller Soehne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"St. John\\'S Wort","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Max Zeller Soehne","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Max Zeller Soehne \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Max Zeller Soehne \/ Undisclosed"},{"orgOrder":0,"company":"Max Zeller Soehne","sponsor":"University of Basel","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Valerian-Hop Extract","moa":"Undisclosed","graph1":"Sleep","graph2":"Phase IV","graph3":"Max Zeller Soehne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Max Zeller Soehne \/ University of Basel","highestDevelopmentStatusID":"11","companyTruncated":"Max Zeller Soehne \/ University of Basel"},{"orgOrder":0,"company":"Max Zeller Soehne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Ze 117","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Max Zeller Soehne","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Max Zeller Soehne \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Max Zeller Soehne \/ Undisclosed"},{"orgOrder":0,"company":"Max Zeller Soehne","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Zeller Entspannung","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Max Zeller Soehne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Max Zeller Soehne \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Max Zeller Soehne \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Max Zeller Soehne

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Valerian-Hop Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sleep Disorders, Circadian Rhythm.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          January 13, 2023

                          Lead Product(s) : Valerian-Hop Extract

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase IV

                          Sponsor : University of Basel

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Ze 117 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 29, 2018

                          Lead Product(s) : Ze 117

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : St. John'S Wort is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 22, 2015

                          Lead Product(s) : St. John\'S Wort

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Zeller Entspannung is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stress Disorders, Traumatic, Acute.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 14, 2014

                          Lead Product(s) : Zeller Entspannung

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank